1. Home
  2. III vs KZIA Comparison

III vs KZIA Comparison

Compare III & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Information Services Group Inc.

III

Information Services Group Inc.

N/A

Current Price

$5.35

Market Cap

197.1M

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$10.63

Market Cap

186.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
III
KZIA
Founded
2006
1994
Country
United States
Australia
Employees
1500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.1M
186.7M
IPO Year
2006
2002

Fundamental Metrics

Financial Performance
Metric
III
KZIA
Price
$5.35
$10.63
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.50
$19.50
AVG Volume (30 Days)
158.8K
293.3K
Earning Date
05-07-2026
06-04-2026
Dividend Yield
4.46%
N/A
EPS Growth
216.67
N/A
EPS
0.12
N/A
Revenue
$192,745,000.00
N/A
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.34
N/A
P/E Ratio
$44.83
N/A
Revenue Growth
4.51
N/A
52 Week Low
$3.74
$4.86
52 Week High
$6.45
$17.40

Technical Indicators

Market Signals
Indicator
III
KZIA
Relative Strength Index (RSI) 69.65 35.49
Support Level $3.86 $5.15
Resistance Level $6.13 $10.49
Average True Range (ATR) 0.15 1.15
MACD 0.00 -0.32
Stochastic Oscillator 89.09 2.15

Price Performance

Historical Comparison
III
KZIA

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: